These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 12830721)
21. Effects of formulation and operating variables on zanamivir dry powder inhalation characteristics and aerosolization performance. Yang Y; Yang Z; Ren Y; Mei X Drug Deliv; 2014 Sep; 21(6):480-6. PubMed ID: 24491208 [TBL] [Abstract][Full Text] [Related]
22. Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations. Mangal S; Meiser F; Tan G; Gengenbach T; Denman J; Rowles MR; Larson I; Morton DA Eur J Pharm Biopharm; 2015 Aug; 94():160-9. PubMed ID: 26007290 [TBL] [Abstract][Full Text] [Related]
23. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients. Razavi Rohani SS; Abnous K; Tafaghodi M Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646 [TBL] [Abstract][Full Text] [Related]
24. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Cheow WS; Ng ML; Kho K; Hadinoto K Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560 [TBL] [Abstract][Full Text] [Related]
26. Raman mapping of mannitol/lysozyme particles produced via spray drying and single droplet drying. Pajander JP; Matero S; Sloth J; Wan F; Rantanen J; Yang M Pharm Res; 2015 Jun; 32(6):1993-2002. PubMed ID: 25504535 [TBL] [Abstract][Full Text] [Related]
27. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers. Zeng XM; MacRitchie HB; Marriott C; Martin GP Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863 [TBL] [Abstract][Full Text] [Related]
28. Feasibility of highly branched cyclic dextrin as an excipient matrix in dry powder inhalers. Kadota K; Senda A; Ito T; Tozuka Y Eur J Pharm Sci; 2015 Nov; 79():79-86. PubMed ID: 26360838 [TBL] [Abstract][Full Text] [Related]
29. [Effect of surface modification on surface energy of lactose and performance of dry powder inhalations]. Jiang RG; Zhang PW; Wang LQ; Liu H; Pan WS; Wang CL Yao Xue Xue Bao; 2005 Apr; 40(4):373-6. PubMed ID: 16011271 [TBL] [Abstract][Full Text] [Related]
30. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method. You Y; Zhao M; Liu G; Tang X J Pharm Pharmacol; 2007 Jul; 59(7):927-34. PubMed ID: 17637186 [TBL] [Abstract][Full Text] [Related]
31. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333 [TBL] [Abstract][Full Text] [Related]
32. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Sou T; Kaminskas LM; Nguyen TH; Carlberg R; McIntosh MP; Morton DA Eur J Pharm Biopharm; 2013 Feb; 83(2):234-43. PubMed ID: 23183447 [TBL] [Abstract][Full Text] [Related]
33. Co-spray-dried poly-L-lysine with L-leucine as dry powder inhalations for the treatment of pulmonary infection: Moisture-resistance and desirable aerosolization performance. Zhang X; Zhou Y; Wang G; Zhao Z; Jiang Z; Cui Y; Yue X; Huang Z; Huang Y; Pan X; Wu C Int J Pharm; 2022 Aug; 624():122011. PubMed ID: 35820517 [TBL] [Abstract][Full Text] [Related]
34. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation. Tang Y; Zhang H; Lu X; Jiang L; Xi X; Liu J; Zhu J Drug Deliv; 2015; 22(5):608-18. PubMed ID: 24299495 [TBL] [Abstract][Full Text] [Related]
35. The effect of operating and formulation variables on the morphology of spray-dried protein particles. Maa YF; Costantino HR; Nguyen PA; Hsu CC Pharm Dev Technol; 1997 Aug; 2(3):213-23. PubMed ID: 9552449 [TBL] [Abstract][Full Text] [Related]
36. Development of inhalable dry powder formulation of basic fibroblast growth factor. Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Nano Spray Dryer B-90 for pharmaceutical applications. Schmid K; Arpagaus C; Friess W Pharm Dev Technol; 2011 Aug; 16(4):287-94. PubMed ID: 20491538 [TBL] [Abstract][Full Text] [Related]
38. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients. Minne A; Boireau H; Horta MJ; Vanbever R Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052 [TBL] [Abstract][Full Text] [Related]
39. Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder. Cai X; Yang Y; Xie X; Yu F; Yang Y; Yang Z; Zhang T; Mei X Drug Deliv; 2016 Jul; 23(6):1962-71. PubMed ID: 26066037 [TBL] [Abstract][Full Text] [Related]
40. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Amaro MI; Tewes F; Gobbo O; Tajber L; Corrigan OI; Ehrhardt C; Healy AM Int J Pharm; 2015 Apr; 483(1-2):6-18. PubMed ID: 25660067 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]